Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Immunol. 2021 Apr 7;206(9):2122–2134. doi: 10.4049/jimmunol.2100018

Figure 8. Prime-boost RSVNanoVax vaccination mediates viral clearance in an outbred population.

Figure 8.

Swiss Webster mice were primed with 500 μg of the indicated nanoparticle formulation i.n. on day 0, and boosted with 500 μg i.n. on day 28. No vaccine mice were administered PBS i.n. at both the prime and boost. RSV immune mice received 4.8 × 106 PFU RSV-A2 i.n. at the prime and PBS i.n. at the boost. All mice were challenged with 4.8 × 106 PFU RSV-A2 on day 56. Infectious viral PFU were quantified in the lung on day 2 or 4 post-infection by plaque assay. Statistical significance was determined by 2-way ANOVA with a Tukey’s post hoc test. ***p<0.001. Data represent mean ± SEM of 2 independent experiments (n=8–10). The horizontal dashed line represents the limit of detection.